RARE: Morgan Stanley Maintains Outperform Rating, April 2026

Morgan Stanley kept its Outperform rating on Ultragenyx Pharmaceutical (RARE) on April 16, 2026, while raising the price target to $67 from $50. The analyst rating maintained reflects confidence in the biotech firm’s rare disease pipeline. RARE trades at $24.52, down 2.66% on the day. The company focuses on ultra-rare genetic disorders with approved products like Crysvita and Mepsevii. This analyst rating maintained decision signals steady conviction despite near-term market volatility.

Morgan Stanley’s Analyst Rating Maintained at Outperform

Price Target Increase Signals Confidence

Morgan Stanley raised its price target on RARE to $67, a 34% increase from the prior $50 target. This analyst rating maintained at Outperform reflects the firm’s belief in Ultragenyx’s long-term value creation. The biotech company trades well below the new target, suggesting upside potential. The rating change came after market close on April 16, 2026.

Current Stock Performance

RARE closed at $24.52, representing a 2.66% decline for the day. The stock trades near its 50-day average of $22.20 but remains significantly below its 52-week high of $42.37. Market cap stands at $2.37 billion. Volume reached 1.81 million shares, slightly below the 2.21 million average. The analyst rating maintained suggests Morgan Stanley sees recovery potential despite recent weakness.

Ultragenyx’s Rare Disease Portfolio Drives Conviction

Approved Therapies and Revenue Growth

Ultragenyx’s commercial portfolio includes Crysvita for X-linked hypophosphatemia, Mepsevii for mucopolysaccharidosis VII, and Evkeeza for familial hypercholesterolemia. Revenue grew 29% year-over-year in 2024, reaching approximately $650 million annually. The company generated $6.73 per share in revenue trailing twelve months. This analyst rating maintained reflects the strength of these approved products and their market expansion potential.

Pipeline Advancement and Gene Therapy Focus

Ultragenyx advances multiple gene therapy candidates, including DTX401 and DTX301 for metabolic disorders. The company also develops GTX-102 for Angelman syndrome and UX143 for osteogenesis imperfecta. These programs address ultra-rare conditions with limited treatment options. Morgan Stanley’s analyst rating maintained suggests confidence in clinical progress and eventual commercialization success.

Financial Metrics and Profitability Challenges

Current Losses and Cash Position

Ultragenyx reported a net loss of $5.76 per share trailing twelve months, reflecting heavy R&D spending. Operating margins stand at -79.6%, typical for biotech firms investing heavily in pipeline development. However, the company maintains a strong cash position with $6.94 per share in cash. Working capital totals $567 million, providing runway for clinical programs. This analyst rating maintained acknowledges the path to profitability remains uncertain but manageable.

Valuation and Growth Trajectory

The price-to-sales ratio of 3.51x appears reasonable for a biotech with 29% revenue growth. Free cash flow remains negative at -$4.72 per share, typical during expansion phases. Meyka AI rates RARE with a grade of B+, reflecting balanced risk-reward dynamics. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guaranteed and we are not financial advisors.

Analyst Consensus and Market Outlook

Broad Buy Support Among Analysts

Wall Street consensus shows 15 Buy ratings and only 1 Hold rating on RARE, with no Sell recommendations. The consensus score of 3.0 reflects strong bullish sentiment. Morgan Stanley’s price target raised to $67 from $50 aligns with this broader optimism. This analyst rating maintained at Outperform positions RARE favorably within the biotech sector.

Technical Setup and Momentum

Technical indicators show mixed signals. The RSI at 62.76 suggests moderate momentum, while the MACD histogram of 0.43 indicates positive momentum. The ADX at 26.19 confirms a strong trend. However, the stock trades below its 200-day moving average of $28.34, suggesting longer-term weakness. This analyst rating maintained may attract value-oriented investors seeking recovery plays in the biotech space.

Meyka AI’s Assessment and Investment Grade

B+ Grade Reflects Balanced Risk Profile

Meyka AI’s proprietary grading system assigns RARE a B+ score of 70.12 out of 100. This grade incorporates S&P 500 benchmark comparison (11%), sector performance (16%), industry metrics (16%), financial growth (12%), key metrics (16%), forecasts (8%), analyst consensus (14%), and fundamental growth (7%). The B+ rating suggests RARE offers reasonable risk-adjusted returns for growth-focused investors.

AI-Powered Market Analysis Platform

Meyka AI provides real-time analyst coverage tracking and price forecasts for 60,000+ stocks globally. The platform’s assessment of RARE reflects both fundamental strength and execution risks. RARE stock analysis on Meyka shows detailed metrics and consensus data. This analyst rating maintained by Morgan Stanley aligns with Meyka’s constructive but cautious stance on the biotech sector.

What’s Next for Ultragenyx and RARE Investors

Upcoming Catalysts and Earnings

Ultragenyx reports earnings on May 5, 2026, providing the next major catalyst. Investors will focus on Q1 revenue trends, pipeline updates, and cash burn rates. The company’s ability to demonstrate revenue growth and clinical progress will determine whether Morgan Stanley’s analyst rating maintained holds or shifts. Gene therapy approvals could accelerate upside significantly.

Risk Factors and Considerations

Biotech stocks carry inherent risks including clinical trial failures, regulatory setbacks, and competitive pressures. Ultragenyx’s negative cash flow and operating losses require continued capital access. Patent expirations on approved products pose long-term threats. This analyst rating maintained reflects Morgan Stanley’s belief these risks are manageable given the company’s portfolio strength and market opportunity in rare diseases.

Final Thoughts

Morgan Stanley’s decision to maintain its Outperform rating on Ultragenyx while raising the price target to $67 reflects confidence in the company’s rare disease strategy. RARE trades at $24.52, offering potential upside to the new target. The analyst rating maintained signals that Morgan Stanley sees value despite near-term stock weakness and ongoing losses. Ultragenyx’s approved therapies generate meaningful revenue, while its gene therapy pipeline offers long-term growth potential. The company’s $567 million working capital provides adequate runway for clinical development. Meyka AI’s B+ grade aligns with the broader bullish consensus, though execution risks remain. Investors should monitor Q1 earnings on May 5 and clinical trial progress. The biotech sector remains volatile, and RARE’s path to profitability depends on pipeline success and revenue acceleration. For growth-oriented investors with higher risk tolerance, the analyst rating maintained and raised price target suggest a constructive setup, though careful position sizing is warranted given the company’s current losses and cash burn dynamics.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.